Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 215 of 5804
-
Can a Two-Dose drug delay type 1 diabetes as well as a 14-Day treatment?
Disease control Not yet recruitingThis is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at l…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New device could ease lung pressure in heart failure patients
Disease control Recruiting nowThe goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associ…
Phase: NA • Sponsor: Pulnovo Medical, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New antibody drugs aim to prevent deadly clots in PAD patients after leg surgery
Disease control Recruiting nowThis study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for kids with aggressive brain cancer: hormone therapy plus chemo
Disease control Not yet recruitingThis is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront ther…
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood test may spare lung cancer patients from chemo
Disease control Not yet recruitingAnti-PD-1 monotherapy has demonstrated significant clinical efficacy in advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score \[TPS\] \>50%), outperforming platinum-based chemotherapy in terms of objective response rate (ORR)…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo aims to shrink skin cancer before surgery
Disease control Not yet recruitingThe NEOPECS trial is a phase II prospective, single-arm, non-randomised interventional trial for patients with borderline resectable locally advanced cutaneous squamous cell carcinoma with a 6-participant safety lead in to ensure safety of the combination in the neoadjuvant setti…
Phase: PHASE2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Growing heart valve could spare kids multiple surgeries
Disease control Not yet recruitingProspective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects…
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail takes on rare skin cancer
Disease control Not yet recruitingVG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogam…
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising drug cocktail aims to shrink penile cancer before surgery
Disease control Not yet recruitingThis clinical study is a Phase II research trial focused on a new preoperative treatment for men with advanced penile squamous cell carcinoma (a type of penile cancer). The cancer may be hard to treat with penile-sparing surgery, or it may have spread to nearby lymph nodes (like …
Phase: PHASE2 • Sponsor: Jiyan Liu • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis study is a single-arm, open-label clinical investigation to evaluate the tolerance, safety and preliminary efficacy of CAR-T (U96) in the treatment of relapsed/refractory B-cell tumors. The study will be conducted in two disease types, acute B-lymphoblastic leukemia and B-ce…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug trial aims to ease muscle weakness in rare disease
Disease control Not yet recruitingThe primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for Hard-to-Treat blood cancer
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lacutoclax is a potent and selective BCL-2 inhibitor…
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for tough lymphoma: TR115 faces off against standard care
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and/or refractory peripheral T/NK…
Phase: PHASE3 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Handheld breath test could spot lung disease early
Diagnosis Not yet recruitingThis is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway o…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
Could a new drug help keep myasthenia gravis symptoms at bay?
Disease control Recruiting nowThe primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Phase: PHASE2 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New heart pump aims to make risky angioplasty safer
Disease control Not yet recruitingThis study aims to evaluate the safety and effectiveness of the VentriCure interventional left ventricular assist system for short-term ventricular support during high-risk percutaneous coronary intervention (HRPCI) in non-emergent, hemodynamically stable coronary artery disease …
Phase: NA • Sponsor: Life Shield Medical Technology Co., LTD • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
AI chat could be a secret weapon against dementia in lonely seniors
Disease control Not yet recruitingThis randomized controlled trial examines the mechanisms of conversational AI-based interventions for early dementia prevention in socially isolated older adults.
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Double-Drug attack on Hard-to-Treat cancers
Disease control Not yet recruitingThis open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on, are intolerant to, or lack standard therapy. The Pha…
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Scientists deliberately infect volunteers with dengue to unlock immune secrets
Knowledge-focused Recruiting nowBackground: Dengue is a viral disease spread by mosquitoes. Most people bitten by mosquitoes carrying dengue viruses do not get sick, but severe cases can cause shock, internal bleeding, and death. There are no treatments for dengue. To develop treatments, researchers need to un…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC